Dermatology

Top Medical News
Elvira Manzano, 2 days ago
Patients with psoriasis taking the immunosuppressant methotrexate had low antibody responses to SARS-CoV-2 after receiving the first dose of Pfizer-BioNTech’s BNT162b2 vaccine but had shown T-cell responses, according to a study that was the first to look at T-cell responses in patients taking methotrexate.
Roshini Claire Anthony, 13 Jul 2021

Bimekizumab appeared to be more effective than secukinumab in improving skin clearance in patients with moderate-to-severe plaque psoriasis, according to the multinational, phase IIIb BE RADIANT trial presented at AAD 2021.

13 Jul 2021
Use of the highly selective oral Bruton’s tyrosine kinase inhibitor tirabrutinib appears effective in the treatment of patients with refractory pemphigus, inducing remission and cutting oral corticosteroid use without major safety concerns, according to data from a phase II trial.
12 Jul 2021
A short interval as compared to a long one between the primary melanoma excision and obtaining a sentinel lymph node biopsy specimen demonstrate similar patient outcomes, reports a recent study.
10 Jul 2021
A systematic review and network meta-analysis of studies assessing small molecule inhibitors and biologic drugs show that tofacitinib and ixekizumab are the most effective treatments for nail psoriasis in 10 to 16 weeks and 24 to 26 weeks, respectively.
10 Jul 2021
Low-dose skin electron beam therapy using a rotational technique demonstrates a very high overall response rate and an improvement in skin-related quality of life (QOL) in patients with mycosis fungoides, the most common form of cutaneous T-cell lymphoma, reports a recent study.
09 Jul 2021
Topical terbinafine 10% solution (MOB-015) is a viable option for the treatment of mild-to-moderate distal subungual onychomycosis, with an adverse event profile similar to vehicle, suggests a study.
Special Reports
16 Jun 2021
Furfuryl Palmitate
10 Dec 2019
Oral H1-antihistamines are the initial treatment of choice for allergic rhinitis (AR) and chronic urticaria in the primary care setting. However, in a diverse population of patients with AR and urticaria, primary care physicians are faced with the challenge of prescribing the best therapy amid a wide armamentarium of antihistamines available.
22 Oct 2019
Topical silicone gel is considered first-line therapy against scars and is used particularly for the treatment of elevated scars,such as hypertrophic and keloid scars. In this report, Dr Yong shares his clinical experience of using silicone gel as part of his scar management strategies.
01 Nov 2018
The prevalence of allergic diseases in the Asia-Pacific region is expected to rise over the next 20 years, driven by rapid economic development and urbanization. Allergic diseases have high socioeconomic impact by impairing productivity and quality of life, and the impact may be greater in Asia-Pacific than in Europe due to the presence and predominance of perennial allergens.
31 Jul 2018
A wound is a disruption of the normal structure and function of the epidermis. Wounds maybe caused by acute traumatic injury to the skin, or other aetiologies that cause initially intact skin to break down. Recently, Dato’ Dr Ho Teik Kok shared his insights into the importance of micronutrients for wound recovery, stressing on the importance of treating the underlying diseases that may impede wound healing.
Dr. Steven Ang, Dr. Leo Kah Woon, 11 Jul 2018
DCH Auriga recently held their first Aesthetics and Suturing Workshop under the IMPACT continuing medical education series – a scientific platform that aims to cascade the latest updates on disease management and share best clinical practices among healthcare professionals in Singapore. Two experts on aesthetics and aesthetic surgery shared their insights on suturing techniques and current approaches for scar prevention and management.
22 Dec 2017
Eczema (atopic dermatitis) is a chronic inflammatory skin disease that can present in many different forms. However, it is principally characterized by dry skin, intense itching, and the presence of inflammatory skin lesions. [J Eur Acad Dermatol Venereol 2016;30:604-618; N Engl J Med 2008;358:1483-1494; Lancet 2016;387:1109-1122]
Conference Reports
Roshini Claire Anthony, 13 Jul 2021

Bimekizumab appeared to be more effective than secukinumab in improving skin clearance in patients with moderate-to-severe plaque psoriasis, according to the multinational, phase IIIb BE RADIANT trial presented at AAD 2021.

Roshini Claire Anthony, 16 Jun 2021

Patients with psoriasis may be at an increased risk of contracting COVID-19, according to a study presented at AAD VMX 2021.

Elaine Soliven, 04 Jun 2021
Daily application of M89, which contains 89% Vichy volcanic mineralizing water (VVMW) and 0.4% hyaluronic acid, significantly improves skin characteristics in individuals with clinical signs and symptoms of rosacea, according to a study presented at AAD 2021.
Elaine Soliven, 01 Jun 2021
Treatment with ruxolitinib cream improves sleep-related impairment (SRI) and sleep disturbance in adolescent and adult patients with atopic dermatitis (AD), based on two phase III studies presented at AAD 2021.
Audrey Abella, 27 May 2021
The high-affinity, humanized, anti-interleukin-23-p19 monoclonal antibody tildrakizumab showed durable efficacy and safety for the treatment of chronic plaque psoriasis, according to the week 256 findings of the reSURFACE 1 trial.
Roshini Claire Anthony, 25 May 2021

Bimekizumab, a monoclonal IgG1 antibody that selectively inhibits interleukin-17A and interleukin-17F, was superior to adalimumab in reducing the severity of plaque psoriasis, according to results of a phase III trial presented at AAD 2021.

Audrey Abella, 25 May 2021
In adults with moderate-to-severe atopic dermatitis (AD), use of the oral, selective Janus kinase 1/2 inhibitor baricitinib* led to significant improvements in quality of life (QoL) parameters in AD, accordingly to subgroup analyses results of the BREEZE-AD5 trial.